MARIZYME, INC.
company.status.inactiveCIK 1413754fmd_1YFDV8MBTPQ58N5RZ2FAH3EFNA制造业 · 外科及医疗器械模板: 标准
覆盖范围: 2010年1月01日 至 2024年9月30日，共 52 个期间
| 项目 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 营业成本 | 0 | 0 | 0 | 0 | 0 | 0 | – | 0 | 0 | 0 |
| 毛利润 | 0 | 0 | 0 | 0 | 0 | 0 | – | 0 | 0 | 0 |
| 信用损失准备 | 2 | 2 | 0 | 0 | – | – | – | – | – | – |
| 研发费用 | – | – | – | – | – | – | 1 | 2 | 4 | 2 |
| 营业费用合计 | 1 | 1 | 0 | 0 | 0 | 1 | 6 | 9 | 38 | 35 |
| 营业利润 | (1) | (1) | (0) | (0) | (0) | (1) | (6) | (9) | (37) | (34) |
| 利息费用 | – | – | – | – | – | – | 0 | – | – | – |
| 利息及投资收益 | – | – | – | – | – | – | – | – | – | – |
| 其他营业外收入（支出） | (9) | (8) | (1) | (0) | (0) | – | (0) | (2) | (1) | (35) |
| 税前利润 | – | – | – | – | – | – | – | – | – | – |
| 所得税费用 | – | – | – | – | – | – | – | – | – | – |
| 持续经营净利润 | – | – | – | – | – | – | – | – | – | – |
| 净利润 | (10) | (9) | (1) | (1) | (0) | (1) | (6) | (11) | (38) | (70) |
| 归属于普通股股东的净利润 | – | – | – | – | – | – | – | – | – | – |